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Strengths and limitations of this study
 ► First randomised controlled trial on bilateral lower 
extremity nerve decompression surgery with proper 
control group.
 ► Substantial 4 years of follow- up to study long- term 
outcomes (ie, ulcer and amputation incidence).
 ► First randomised controlled trial using cost effec-
tiveness as endpoint.
 ► It is not feasible to blind the patients for the allocated 
treatment. Sham surgery is considered unethical.
AbStrACt
Introduction The peripheral nerves of patients with 
diabetes are often pathologically swollen, which results 
in entrapment at places of anatomical narrowing. 
This results in nerve dysfunction. Surgical treatment 
of compression neuropathies in the lower extremities 
(lower extremity nerve decompression (LEND)) results in 
relief of symptoms and gain in peripheral nerve function, 
which may lead to less sensory loss (short term) and less 
associated detrimental effects including foot ulceration 
and amputations, and lower costs (long term). The aim of 
the DeCompression trial is to evaluate the effectiveness 
and (cost- )effectiveness of surgical decompression of 
compressed lower extremity nerves (LEND surgery) 
compared with patients treated with conventional (non- 
surgical) care.
Methods and analysis A stratified randomised (1 to 1) 
controlled trial comparing LEND surgery (intervention) 
with conventional non- surgical care (control strategy) 
in subjects with diabetes with problems of neuropathy 
due to compression neuropathies in the lower extremity. 
Randomisation is stratified for participating hospital 
(n=11) and gender. Patients and controls have the same 
follow- up at 1.5, 3, 6, 9, 12, 18, 24 and 48 months. 
Participants (n=344) will be recruited in 12 months and 
enrolled in all affiliated hospitals in which they receive 
both the intervention or conventional non- surgical care 
and follow- up. Outcome assessors are blinded to group 
assignment. Primary outcome: disease- specific quality 
of life (Norfolk Quality of Life Questionnaire—Diabetic 
Neuropathy). Secondary outcomes: health- related quality 
of life (EuroQoL 5- dimension 5- level (EQ- 5D5L), 36- 
item Short Form (SF-36)), plantar sensation (Rotterdam 
Diabetic Foot Test Battery), incidence of ulcerations/
amputations, resource use and productivity loss (Medical 
Cost Questionnaire, Productivity Cost Questionnaire) during 
follow- up. The incremental cost- effectiveness ratio will be 
estimated on the basis of the collected empirical data and 
a cost- utility model.
Ethics and dissemination Ethics approval has been 
granted by the Medical Research Ethics Committee 
of Utrecht University Medical Center (reference: 
NL68312.041.19v5, protocol number: 19-335/M). 
Dissemination of results will be via journal articles and 
presentations at national and international conferences.
trial registration number NetherlandsTrial Registry 
NL7664.
IntroduCtIon
Current non- surgical care does not have satis-
fying treatments for the tingling, burning, 
electrical and painful symptoms of neurop-
athy and patients have nowhere to go when 
seeking treatment for the concomitant 
numbness in their feet. Refractory to thera-
pies like antidepressants and anticonvulsants, 
symptoms are not treated to satisfaction and 
the numbness is sadly observed. Neurop-
athy lowers the quality of life and precedes 
diabetic foot disease.1–3 Up to 60% of patients 
with diabetes will be confronted with neurop-
athy. It has been estimated that the incidence 
of diabetic foot ulcers (DFUs) at some point 
during the disease is about 15%.4 DFUs 
precede 8 out of 10 non- traumatic ampu-
tations and the all- cause mortality rate after 
5 years is 39%–80%.5–7 This is equivalent to 
the mortality rates of lung and colorectal 
cancers.8
The costs for society are sizeable: the 
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827.9 10 In the Netherlands, over one million people have 
diabetes and the incidence (2.8–3.5/1000 inhabitants) 
is still rising. In line with aims and priorities defined by 
the International Working Group on the Diabetic Foot 
(IWGDF), more effective treatments for our diabetic 
population are urgently needed. It is now acknowledged 
that many patients with symptoms of neuropathy also 
have localised nerve compressions, which contribute to 
the symptoms.11 Nerves in the legs and feet also suffer 
from this phenomenon, which are treated surgically by 
releasing the nerve from the site of compression. In this 
way, blood flow in the nerve is restored and processes of 
nerve regeneration are allowed, which relieves symptoms 
and may consequently result in gain of sensory function.12 
It is assumed that these patients have a lower risk of falls, 
foot ulceration and consequent lower extremity amputa-
tions. Current series report considerable pain relief of >4 
points (0–10 on a Visual Analogue Scale), occurring in 
91% of patients and sensibility improvement in 69% of 
patients. Health- related quality of life (HRQoL) was still 
significantly improved in six out of eight SF-36 domains 
at 24 months and low perioperative and postoperative 
complication rates are reported (pooled wound dehis-
cence rate of 15%).13 14
However, no high- quality real- world data exist in which 
lower extremity nerve decompression (LEND) surgery 
is compared with conventional, non- surgical care in 
the diabetic neuropathy population.15–17 Since conven-
tional non- surgical care for the patient with neuropathy 
outnumbers current practices compared with surgical 
management of entrapped lower extremity nerves, but 
the latter having increasingly positive evidence, it is mean-
ingful to further investigate differences in outcomes in a 
randomised controlled setting.
research aim and objectives
The aim of the DeCompression (DECO) study is to 
further investigate the effectiveness and cost effectiveness 
of LEND surgery.
MEthodS And AnAlySIS
Patient and public involvement
Both a patient panel and patient federation (Patienten 
Vereniging Nederland) were involved in the design of the 
study.
Study design and settings
This study is a multicentre, randomised controlled trial 
(RCT) in which patients with symptomatic neuropathy 
and bilateral compression neuropathies of the poste-
rior tibial nerve at the tarsal tunnel will be allocated into 
decompression surgery versus non- surgical follow- up. 
Additional compression neuropathies of the lower 
extremity will also be assessed (tibial nerve at soleal sling, 
common peroneal nerve at the fibular head, superficial 
peroneal nerve and deep peroneal nerve) and decom-
pressed when in the surgical group.
The study will be performed in 11 centres in the Nether-
lands: Utrecht Medical University Center, Utrecht; Diako-
nessen Hospital, Utrecht; Franciscus Gasthuis & Vlietland 
Hospital, Rotterdam; Maasstad Hospital, Rotterdam; 
Jeroen Bosch Hospital, ‘s Hertogenbosch; Isala Hospital, 
Zwolle; OLVG Hospital, Amsterdam; Amsterdam Univer-
sity Medical Center, AMC, Amsterdam; Amsterdam 
University Medical Center, VUmc, Amsterdam; Anto-
nius Hospital, Nieuwegein and Meander Medical Center, 
Amersfoort.
Patient selection
Eligible for participation are all adult patients with 
diabetes with symptoms of neuropathy in the lower 
extremities who are visiting the outpatient clinics of 
the participating hospitals (figures 1–4). The study 
population concerns patients with type 1 or 2 diabetes 
with neuropathy symptoms (30%–60% of patients with 
diabetes) and with signs of superimposed nerve compres-
sions in the leg (up to 35%).18 Of paramount importance 
is to define how severe the degree of sensory loss is, as 
measure of peripheral nerve function and to estimate the 
likelihood of successful surgery.17 19 20 Additional inclu-
sion and exclusion criteria are shown in box 1.
Patients with symptoms of neuropathy have to be exam-
ined regarding the presence of compression neuropathies 
in the lower extremity, using the physical examination 
(Tinel’s sign) as recommended by the American Asso-
ciation of Neuromuscular and Electrodiagnostic Medi-
cine.18 21 Patients will undergo a thorough screening of 
their lower extremities (sensory tests, vascular status). 
The instruments of the Rotterdam Diabetic Foot (RDF) 
Study Test Battery will categorise each patient in their 
sensory loss, thereby determining whether they will be 
allegeable for LEND surgery.17 21 The RDF Test Battery 
is used as a measure of nerve function and likelihood of 
nerve regeneration after surgery.17 22 The investigator 
assesses foot morphology.
Surgical intervention
Interventions will take place in all affiliated hospitals, 
in which both plastic surgeons and neurosurgeons will 
perform LEND surgery. The aim is to operate patients 
within 6 months after randomisation. A surgical release 
of up to four nerves in one leg will be carried out (the 
common, superficial and deep peroneal nerves and tibial 
nerve at the soleal sling and tarsal tunnel). After release 
of the flexor retinaculum at the tarsal tunnel, the calca-
neal branch and medial and lateral plantar nerves will be 
released via the same incision.23 Postoperatively, patients 
will be allowed to use the operated leg full weight bearing 
immediately and will use a walker for 3 weeks when 
necessary. In the patient who did not have preoperative 
pain and who experiences pain due to nerve regenera-
tion, a regimen of neuropathic pain medication may be 
started, according to the current national protocols on 
neuropathic pain.24 The contralateral leg will be oper-
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Phase 1
All participating centres (n=11)
Diabetic patients with 
symptoms of neuropathy
Local referral in- and exclusion criteria
Phase 2
Specific in- and exclusion criteria
Phase 3
randomisation
LEND surgery Non-surgical care(control)
Figure 1 Study flow chart. LEND, lower extremity nerve 
decompression.
Participating surgeons are trained to standardise the 
method of treatment and number of patients treated is 
recorded.
The following postoperative instructions are given to 
the subjects in the surgical group:
 ► The wound has to stay dry for 7 days.
 ► The patient should keep the operated leg elevated 
when resting.
 ► The patient is allowed to walk small distances the next 
days after the operation.
 ► Long distance walking, running or walking the dog 
is not recommended and is allowed 3 weeks after 
surgery in case of normal wound healing.
 ► Swimming and bathing are allowed after 14 days.
 ► Performing sports is allowed after 3–6 weeks.
 ► Patients will be instructed about wound problems.
 ► Patients need to be instructed when he/she needs to 
contact the hospital.
Conventional non-surgical care
The control group is treated to care as usual, being conven-
tional non- surgical care, and is defined as care in line with 
national and international guidelines for the treatment 
of neuropathy and diabetic foot disease. Non- surgical 
care includes the treatment with analgesics, according to 
the national guideline on painful neuropathy, preventive 
measures and education for patients at risk for diabetic 
foot ulceration. Biomechanical offloading and foot 
infection treatments are provided in both groups, when 
required during follow- up.
randomisation
Patients will be randomised (1:1, stratified for hospital) 
to LEND surgery (intervention group) or current 
conventional non- surgical care (control group), using a 
web- based randomisation system (Castor Electronic Data 
Capture). Randomisation is stratified for centre and 
gender, implying that approximately the same numbers 
of LEND and control patients are treated in each centre. 
We acknowledge that practice variation across centres 
may exist, but this will not bias the overall estimated 
effect size of LEND versus control treatment. Patients 
who decline randomisation will be treated to care as 
usual. After the end of the study, control subjects have 




Primary outcome: to study the influence of LEND surgery 
on disease- specific quality of life as measured on the 
Norfolk Quality of Life Questionnaire—Diabetic Neurop-
athy (Norfolk- QoL- DN) questionnaire, at 48- month 
follow- up.
Description: The Norfolk- QoL- DN questionnaire is 
developed to assess patients’ subjective perceptions of 
symptoms associated with specific nerve fibre damage 
occurring in diabetes and is validated in other popula-
tions.25 26 Questions relate to physical functioning, large 
fibre neuropathy, activities of daily living, symptoms, 
small fibre neuropathy and autonomic neuropathy and 
are summed into a total score. The questionnaire is 
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Phase 1
All participating centres (n=11)
Diabetic patients visiting the outpatient 
clinic
Local referral in- and exclusion criteria




Q: Michigan Neuropathy Screening Instrument
Instrument
MNSI > 3 ?
Nurses Physical examination
Monofilament on hallux, fifth toe and medial 
heel
Palpation of arteries (ADP and ATP)
+ Tinel sign at tarsal tunnel (bilateral)
Informed consent procedure
Figure 2 Study flow chart. LEND, lower extremity nerve decompression; MNSI, Michigan neuropathy screening instrument; 
ADP, a. dorsalis pedis; ATP, a. tibialis posterior; +, positive.
Phase 2
Specific in- and exclusion criteria at referral 
visit
Include patient with Phase 2 inclusion 
criteria
Objective
Study physician + nurses
Role Instrument
+ Tinel at tarsal tunnel (bilateral)
Physical examination (Tinel)
< 2 Tinel + excluded2 Tinel +Informed consent procedure Study physician
Inclusion Study physician - Physical assessments- Questionnairs
Exclusion
Figure 3 Study flow chart.
Secondary objectives are (short term)
1. To study the influence of LEND surgery on balance 
and gait parameters at 24 months.
Secondary outcome: the difference between pedobar-
ographic and pedothermographic imaging results be-
tween the intervention and control group.
Description: pedobarographic imaging will be used 
to assess differences in plantar pressure distributions 
during standing and gait. Pedothermographic imag-
ing will assess differences in vascular supply at the foot 
sole. Increased plantar pressure relates to the devel-
opment of DFUs.27 Temperature measurements are 
shown to be of value in the prediction of tissue break-
down.28–30 The before mentioned measurements are 
carried out at baseline and 12 and 24 months of follow- 
up (table 1).
2. To study to what extent preoperative electrodiagnostic 
studies (used to grade the severeness of diabetic senso-
rimotor polyneuropathy (DSP)) account for the varia-
tion in surgical outcome (HRQoL: Norfolk- QoL- DN, 
SF-36, EQ- 5D) at 24 months.
Secondary outcome: the influence of electrodiagnos-
tic parameters (compound muscle action potential 
(CMAP), distal motor latency (DML), sensory nerve 
action potential (SNAP)) on the difference in scores of 
HRQoL between the intervention and control group.
Description: since diabetes induces nerve damage, 
surgical outcome after LEND is presumably relat-
ed to the degree of preoperative nerve functioning. 
To assess this relationship, validated electrodiagnos-
tic parameters are used to grade nerve functioning, 
as well to monitor nerve parameters during follow- 
up, according to an established protocol from the 
Rotterdam Study.31
3. To study to what extent preoperative nerve damage in-
fluences the results of LEND surgery on balance and 
gait parameters, Visual Analogue Scale (VAS) neurop-
athy scores, HRQoL and symptoms at 24 months.
Secondary outcome: the influence of RDF Test Battery/
quantitative sensory testing (QST) scores on the differ-
ence in balance and gait parameters, VAS neuropathy 
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LEND surgery Non-surgical care(control)
Figure 4 Study flow chart. LEND, lower extremity nerve 
decompression.
box 1 Inclusion and exclusion criteria.
Inclusion criteria
In order to be eligible to participate in this study, a subject must meet 
all of the following criteria:
 ► Having diabetes mellitus (type 1 or 2).
 ► Patients (>17 and <76 years old).
 ► Symptoms of neuropathy (assessed with the Michigan Neuropathy 
Screening Instrument, scoring >3).
 ► A bilateral Tinel sign at the tarsal tunnel (posterior tibial nerve).
 ► Sufficient circulation to heal lower extremity incisions (by palpating 
the peripheral arteries of the foot: a palpable dorsal pedis artery or 
posterior tibial artery is needed). In case of non- palpable arteries, a 
pedal Doppler arterial waveform is evaluated. A toe brachial index 
(≥0.75) is performed when the Doppler signal is not triphasic.
 ► Minimal or controlled pedal oedema (assessed with inspection and 
physical examination).
 ► Being fit for surgery.
 ► Compliant with instructions for their own care.
 ► Intact protective sensation (cutaneous threshold <10 g monofila-
ment) at the plantar side of the foot (plantar hallux and fifth toe).
 ► Written informed consent.
Exclusion criteria
A potential subject who meets any of the following criteria will be ex-
cluded from participation in this study:
 ► Diabetic foot ulcer(s) or amputation(s) in history, active radicular 
syndrome or neurological disease interfering with sensation of the 
feet, as assessed in the interview and screening questionnaire (eg, 
HIV and chemotherapy- induced neuropathy).
 ► Previous surgery at lower extremity nerve compression sites.
 ► Active Charcot foot.
 ► Not able to understand written and oral instructions (ie, insufficient 
command of Dutch language).
 ► Being incompetent (incapacitated).
 ► Current enrolment in a clinical trial which involves surgery of the 
lower extremity or medical drug trials investigating the effects on 
neuropathy symptoms.
 ► Glycated hemoglobin (HbA1c) level >11% at baseline.
 ► Pregnant women.
Screening Instrument (MNSI)) between the interven-
tion and control group.
Description: the relationship between the degree of 
preoperative diabetes- induced nerve damage and sur-
gical results of LEND on before mentioned outcomes 
will be assessed.17
Secondary objectives are (long term)
1. To study if LEND surgery is cost effective, compared 
with conventional non- surgical care (HRQoL, resource 
use, productivity loss), at 48 months.
Secondary outcome: the difference between HRQoL, 
resource use (based on data from hospital financial 
systems, general practitioner, national databases) and 
productivity loss (Medical Cost Questionnaire and 
Productivity Cost Questionnaire) between the inter-
vention and control group. Cost effectiveness will be 
evaluated as the incremental cost–utility ratio (ICUR/
incremental cost- effectiveness ratio (ICER)) of LEND 
surgery compared with conventional non- surgical care.
Description: cost effectiveness of LEND compared with 
conventional care is estimated by comparing HRQoL, 
medical costs (resource use due to DFUs, amputations, 
falls) and productivity loss between the two strategies 
at 48 months of follow- up (table 1).
2. The influence of LEND surgery on gain in sensory 
function at 48 months.
Secondary outcome: the difference in RDF Test Battery 
scores and QST between the intervention and control 
group.
Description: since the compression component in neu-
ropathy of peripheral nerves is released with LEND sur-
gery, processes of remyelination and axon outgrowth 
are allowed. To study these processes over time, soma-
tosensory testing of the (foot) skin is conducted at dif-
ferent time points during follow- up (table 1).17 19 20
3. To study to what extent this surgical procedure results 
in lower risk of diabetic foot ulceration, amputation 
and falls at 48 months.
Secondary outcome: the difference in incident diabet-
ic foot ulceration, amputation and falls between the 
intervention and control group.
Description: reinnervation of the skin presumably 
relates to lower odds of lower extremity complica-
tions and falls during follow- up. To study this, besides 
quantification of skin sensation, incident ulceration, 
amputations and falls are monitored during the total 
duration of the study (table 1).
4. To study to what extent preoperative nerve damage 
influences the results of LEND surgery (ie, HRQoL, 
sensory function and the incidence of ulceration, am-
putation and falls) at 48 months.
Secondary outcome: the influence of baseline nerve 
function, as assessed with the RDF Test Battery and 
QST instruments, on HRQoL, RDF Test Battery 
scores, QST, incident ulceration, amputation and 
falls.
Description: it is expected that the degree of preopera-
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Study ProCEdurES
Utrecht Medical University Center is the coordinating 
centre and responsible for training the participating 
surgeons in both the anatomy lab and during live surgery 
demonstrations. Outcomes will be evaluated in terms of 
HRQoL (Norfolk QoL- DN, EQ- 5D- 5L, SF-36), balance 
and gait parameters, sensory function, incident ulcer-
ation, amputation and falls, resource use and productivity 
loss (table 1). The follow- up moments are at 1.5, 3, 6, 9, 
12, 18, 24 and 48 months and include clinical checkups 
and wound checkups. Outcome assessors are blinded to 
group assignment (locations of incisions are blinded, and 
patients are instructed before the assessment). Patients 
will be asked regarding their resource use according to 
the intervals.
All participants are treated according to current stan-
dards of diabetic foot care, according to national and 
international (IWGDF) guidelines. The duration of 
the study is 5 years in total. Inclusion of participants is 
expected to last 12 months in total. The follow- up period 
is 48 months.
Laboratory results and relevant data on the medical 
history will be retrieved from the patient file. In screening 
patients on neuropathy symptoms, the MNSI will be used. 
Degree of neuropathy symptoms will also be evaluated 
with the VAS and will be used for both legs and feet sepa-
rately. The VAS is a straight line, the ends of which are the 
extreme limits of the sensation being assessed. The line 
is 10 cm in length, using a 10- point scale ranging from 
1 to 10, with 1 being barely perceptible and 10 being 
intolerable. All patients are given questionnaires to assess 
baseline neuropathy symptoms (Norfolk QoL- DN) and 
quality of life (SF-36, EQ- 5D5L).
Sensory status
The RDF Study Test Battery consists of monofilament 
testing, two- point discrimination, vibration sense testing 
and questions on previous ulcers/amputations and its 
clinical utility has been validated.19 20 The RDF Study Test 
Battery instruments (tuning fork, monofilament) are vali-
dated and part of both the neuropathy and diabetic foot 
care guidelines.32 The total time needed to execute the 
tests of the RDF Study Test Battery is approximately 30 
min.
Quantitative sensory testing
To study the effects of LEND surgery on sensory loss (small 
and large fibre functions) and sensory gain (hyperalgesia, 
allodynia (ALL), hyperpathia), we combine the instru-
ments of the RDF Test Battery with the instruments used 
in the battery of the German Research Network on Neuro-
pathic Pain (DFNS). In two centres (in total 80 patients, 
40 in each arm), the QST measurements will be carried 
out. The DFNS instruments measure thermal detection 
thresholds for the perception of cold, warm and paradox-
ical heat sensations (PHS), thermal pain thresholds for 
cold and hot stimuli, mechanical pain sensitivity (MPS) 
including thresholds for pinprick and blunt pressure, a 
stimulus- response function for pinprick sensitivity and 
dynamic mechanical ALL and pain summation to repet-
itive pinprick stimuli. The procedures described below 
are derived from and according to the QST protocol for 
clinical trials of the DFNS and are applied at the plantar 
side of the foot.33
Thermal detection, thermal pain thresholds and PHS
The tests for thermal sensation are performed using a 
TSA (MEDOC, Israel) thermal sensory testing device. 
Cold detection threshold and warm detection threshold 
are measured first. The number of PHS is determined 
during the thermal sensory limen procedure (the differ-
ence limen for alternating cold and warm stimuli), 
followed by cold pain threshold, and heat pain threshold. 
Of three consecutive measurements, the mean threshold 
temperature is calculated. All thresholds are obtained 
with ramped stimuli (1°C/s) that are terminated when 
the subject presses a button. Cut- off temperatures are 0°C 
and 50°C. The baseline temperature is 32°C (centre of 
neutral range) and the contact area of the thermode is 
7.84 cm2. During the session, subjects are not able the 
watch the computer screen. All tests are first demon-
strated over an area that is not tested in the session.
Mechanical pain threshold (MPT) for pinprick stimuli
MPT is measured using a set of seven custom- made 
weighted pinprick stimulators that exert forces between 
8 and 512 mN. Using the method of limits, the final 
threshold is the geometric mean of five series of ascending 
and descending stimulus intensities.
Stimulus-response functions: MPS for pinprick stimuli and 
dynamic mechanical ALL for stroking light touch
MPS is tested using the same weighted pinprick stimula-
tors as for MPT. To obtain a stimulus- response function, 
these seven pinprick stimuli are applied in a balanced 
order, five times each, and the subject is asked to give a 
pain rating for each stimulus on a 0–100 numerical rating 
scale (‘0’ indicating ‘no pain’, and ‘100’ indicating ‘most 
intense pain imaginable’). Stimulus- response functions 
for dynamic mechanical ALL are determined using a set 
of three light tactile stimulators: a cotton wisp exerting a 
force of ±3 mN, a cotton wool tip fixed to an elastic strip 
exerting a force of ±100 mN and a standardised brush 
(Somedic, Sweden) exerting a force of ±200–400 mN. 
The three tactile stimuli are applied five times each with a 
single stroke of approximately 1–2 cm in length over the 
skin. They are intermingled with the pinprick stimuli in 
balanced order and subjects are asked to give a rating on 
the same scale as for pinprick stimuli.
Wind-up ratio (WUR): the perceptual correlate of temporal pain 
summation for repetitive pinprick stimuli
In this test of temporal summation, the perceived magni-
tude of a single pinprick stimulus was compared with that 
of a train of 10 pinprick stimuli of the same force repeated 
at a 1/s rate (256 mN). The train of pinprick stimuli is 
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to give a pain rating representing the pain at the end of 
the train using a numerical rating scale. Single pinprick 
stimuli are alternated with a train of 10 stimuli until both 
are done five times at five different skin sites. The mean 
pain rating of trains divided by the mean pain rating to 
single stimuli is calculated as WUR.
Pressure pain threshold (PPT)
The pressure pain threshold (PPT) is determined with 
three series of ascending stimulus intensities, each applied 
as a slowly increasing ramp of 50 kPa/s, using a pressure 
gauge device (FDN200, Wagner Instruments, USA).
The total time needed to execute the tests of the DFNS 
protocol is approximately 20 min.
Electrodiagnostic tests
In two centres (in total 80 patients, 40 in each arm), the 
electrodiagnostic tests will be carried out, according to 
the protocol of the Rotterdam Study.31 The sural sensory 
nerve will be measured bilaterally and the peroneal motor 
nerve unilaterally, since these nerves are considered the 
most sensitive to detect DSP. The distal peroneal nerve 
CMAP amplitude and DML are recorded at the extensor 
digitorum brevis muscle. Stimulation is applied to the 
anterior side of the ankle, 8 cm proximal to the recording 
electrode. CMAP baseline peak amplitudes below 1.1 mV 
and DML values above 6.5 ms are considered abnormal. 
Sural SNAP amplitudes are measured bilaterally with a 
standard recording electrode placed behind the lateral 
malleolus. Stimulation is applied on the posterior side of 
the calf, 14 cm proximal to the recording electrode. SNAP 
baseline peak amplitudes below 4.0 μV are considered 
abnormal. Electrophysiology is performed using standard 
techniques of percutaneous supramaximal stimulation.
balance and gait
In two centres (in total 80 patients, 40 in each arm), 
balance and gait parameters will be obtained. A pedo-
barographic and pedothermographic image will be made 
of both feet of each patient. The pedobarographic image 
will be made using a platform with pressure sensors 
measurement system (Tekscan Matscan, Massachusetts, 
USA or similar) and a pedothermographic image of the 
microvasculature will be made using an infrared camera 
(FLIR ONE Pro, FLIR Systems, Oregon, USA). Both 
pedobarographic and pedothermographic images will 
be made of both feet of each patient. The pedothermo-
graphic image will be obtained after a 15 min acclima-
tisation period in an air- conditioned room (ie, constant 
temperature and humidity). The plantar surface of 
both feet will be recorded during unloaded conditions. 
Next, patients will be asked to stand for 3 min on a dedi-
cated polyethylene thermographic ‘foot mirror’, while 
recording the dynamic change of the pedothermographic 
image. For the pedobarographic measurements, patients 
will be asked to walk barefooted 5 times over a measure-
ment system using a 2- step protocol with a self- selected, 
but constant walking speed.
Incidence of falls, ulcers and amputations
The incidence of falls, ulcers and amputations will be 
assessed at 6- month intervals. Ulcer characteristics will be 
determined using the IWGDF Perfusion, Extent, Depth, 
Infection and Sensation (PEDIS) and Society for Vascular 
Surgery Wound, Ischemia and foot Infection (WIfI) clas-
sification systems.34 35
SAMPlE SIzE CAlCulAtIon
Sample size was calculated as a difference in quality of 
life of the total Norfolk- Qol- DN score at 48 months 
(primary outcome), based on our own RDF Study cohort 
data and the literature on LEND surgery.33 The sample 
size calculation was based on the natural logarithm- 
transformed Norfolk QoL scores, given the skewness 
of these data. The mean of the ln- transformed scores 
is 2.46. The SD is 1.058. For this superiority study ques-
tion, we used the usual parameters: type I error=5% (two 
sided) and type II error=20% (power=80%). A minimal 
15% reduction of symptoms is anticipated after LEND 
surgery, which resulted in a total sample size of 129 per 
group, ratio=1:1). Adjusting for an anticipated 25% lost 
to follow- up renders our total study size to be 344 patients 
(129*100/75=172 patients per group (±32 patients per 
centre (n=11)). These numbers are also sufficient to 
demonstrate a reduction in the other outcome measures 
between the groups, such as ulceration rates: 2% vs 15% 
at 48 months (alpha=0.05 (two sided), beta=0.20 (power 
80%), ratio=1:1, corrected for multiple testing.14
dAtA CollECtIon, MAnAgEMEnt And AnAlySIS
All patients will be analysed according to the schedule 
in table 1. Data from initial visits, hospitalisation and 
follow- up visits will be entered into a database via an elec-
tronic data capture system (Castor EDC). Data will be 
recorded and analysed without any personal identifiers 
by using coded information. Source documents and iden-
tifiers will be archived. All analysis will be performed on 
the basis of intention to treat. Reporting of this RCT will 
be performed according to the Consolidated Standards 
of Reporting Trials/Consolidated Health Economic Eval-
uation ReportingStandards (Enhancing the QUAlity and 
Transparency Of Health Research) guidelines. Missing 
data will be reported and handled with depending on the 
mechanism of missingness within the DECO- trial dataset.
Statistical analyses
The difference between groups in change between base-
line and follow- up in QoL will be used as primary outcome. 
Baseline characteristics will be described with conven-
tional statistics: means (95% CI) for continuous variables 
with normal distributions, medians (IQR) for variables 
with skewed distributions and the χ2 test (or Fisher’s exact 
test, if appropriate) for discrete variables. Between- group 
comparison of the primary endpoint (Norfolk Qol- DN 
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analysis with time, allocated group and time * allocated 
group as determinants. Stratified for randomisation are 
hospital and number of nerves involved. Basically, the 
same method will be followed for analysis of EQ- 5D5L 
and SF-36 profiles, over time (a different method may be 
selected, depending on the precise shape of the distribu-
tions). Between groups comparisons of sensory function 
will be performed using Wilcoxon rank- sum test repeated 
measurement analysis. The between- group cumulative 
incidence of DFU, amputations and falls will be tested 
using the χ2 test. Between groups comparison of the time 
to these events will be estimated using Kaplan- Meier anal-
ysis. The role of preoperative loss of sensation (nerve 
damage) as a possible effect modifier of effectiveness 
will be studied by adding this variable to the repeated 
measurements and the Kaplan- Meier analysis. Differences 
in surgical outcome are investigated by assessing possible 
effect modifiers like hospital, surgeon’s experience and 
patient factors. Between group comparisons of balance 
and gait parameters will be performed using Wilcoxon 
rank- sum test repeated measurement analysis. Regression 
analysis will be used to study the influence of preoper-
ative electrodiagnostic parameters on Norfolk QoL- DN 
symptom scores at 24 months. Regression analysis will 
be used to study the influence of preoperative RDF Test 
Battery scores on balance and gait parameters, VAS pain 
scores, HRQoL and symptoms at 24 months. Parameters 
on preoperative nerve damage as possible effect modifier 
of effectiveness will also be studied by adding this vari-
able to the repeated measurements and the Kaplan- Meier 
analysis.
Cost-effectiveness analyses
We will assess the cost effectiveness of LEND surgery 
versus conventional non- surgical care over a period of 
48 months. We will perform a cost–utility analysis using a 
disease progression model, quality of life and costs data. 
Cost effectiveness will be evaluated as the ICUR (ICUR/
ICER) of LEND surgery compared with conventional non- 
surgical care. The CI of the ICUR point estimate will be 
obtained with bootstrapping. Data from the DECO study 
will be used to quantify length of life (survival), quality of 
life (based on the EQ- 5D5L utility scores for which ‘Dutch 
tariffs’ are available) and costs. In the view of the long- 
term study perspective, estimated costs are adjusted for 
inflation (Gross Domestic Product (GDP) index) as well 
as for societal time preference (discounting). Uncertainty 
of the estimated ICUR will be quantified using univariate 
sensitivity analysis (‘tornado’ plots) and probabilistic 
sensitivity analysis, depicted as cost- effectiveness plane 
and acceptability curves. Heterogeneity will be studied 
in subgroup analyses, in order to resolve uncertainty and 
guide subgroup- specific treatment decisions.36 37 Exam-
ples of subgroups include age, duration of diabetes, meta-
bolic control, socioeconomic status (level of education 
and current activities of daily life) and degree of nerve 
damage at study entry. Estimating the cost–utility accept-
ability curves of both treatment strategies and value of 
information analysis will support decision- making. The 
economic analysis will be based on the societal perspec-
tive and on the healthcare perspective in which the 
direct medical and productivity costs in both groups will 
be compared. The friction cost method will be used to 
estimate the indirect costs of disease, which explicitly 
considers economic circumstances that limit production 
losses due to disease, according to recent Dutch guide-
lines. The costs per unit of medical consumption will be 
estimated, using the methods from the most recent Dutch 
Manual for Costing in Economic Evaluations. The biggest 
gain in lowering costs is expected from the long- term 
prevention of diabetic ulcers and amputations. Other 
factors include time to ulcer and remaining life expec-
tancy. Hospital data will be used to estimate the costs of 
surgery. Implementation costs of training surgeons will be 
considered.
The study will be monitored by Julius Center, Zeist, 
the Netherlands. At least one monitoring visit per year 
per centre will be conducted. During the complete study 
period, all adverse events will be reported (table 1).
EthICS And dISSEMInAtIon
The study will be conducted according to the principles 
of the Declaration of Helsinki and in accordance with 
the Medical Research Involving Human Subjects Act and 
General Data Protection Regulation. Previous studies 
have proven that LEND surgery has beneficial effects 
on the pain and restoration of sensation in patients with 
neuropathy symptoms. However, the long- term effects of 
LEND surgery are not yet known regarding restoration 
of sensation, prevention of ulceration and amputations 
and cost effectiveness, compared with conventional non- 
surgical care. Recruitment of patients starts in November 
2019 and will be finished when all 344 patients have been 
followed up for 4 years, which is expected at the end of 
2024.
dISCuSSIon
A proper RCT, designed and based on thorough knowl-
edge of peripheral nerve pathology, its associated surgical 
treatments and patient selection, does not yet exist in 
the current literature and is much needed to breach this 
status quo. Since current care does not provide a solu-
tion to the refractory problems of neuropathy, and the 
incidence of diabetes is still rising, new treatments like 
LEND surgery might give solutions regarding efficacy 
and expediency. RCTs on LEND surgery are pled for in 
the medical community and our previous work, the RDF 
study, forms the perfect precursor of the DECO trial.38 39
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